Abstracts tagged "inflammatory arthritis and interleukins (IL)"

Abstract Number: 946 • 2013 ACR/ARHP Annual Meeting
Interleukin-34 Regulates Angiogenesis and Cell Proliferation In Inflammatory Arthritis, This Effect Is Potentiated By Hypoxia
Emese Balogh¹, Mary Connolly¹, Monika Biniecka¹, Jennifer McCormick², Douglas J. Veale³ and Ursula Fearon², ¹Rheumatology, Translation Research Group, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ³Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland
Background/Purpose: Interleukin-34 (IL-34) is a cytokine implicated in macrophage differentiation, angiogenesis and osteoclastogenesis in inflammatory arthritis (IA). IA is characterized by synovial hypoxia, increased oxidative…
Abstract Number: 144 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety of Canakinumab in Patients with Gouty Arthritis
Alexander So¹, Reike Alten², H. Ralph Schumacher³, Mark Bloch⁴, Thomas Bardin⁵, Markus R. John⁶, Gerhard Krammer⁶, Jan Michael Nebesky⁶, Aiyang Tao⁷ and Naomi Schlesinger⁸, ¹Rheumatology, CHUV, Univ of Lausanne, Lausanne, Switzerland, ²Charité Univ Medicine, Berlin, Germany, ³Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Rheumatology, Hôpital Lariboisière, Paris, France, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁸UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: Gouty arthritis (GA) is a chronic inflammatory disease. Targeting the inflammatory pathway through IL-1β inhibition with canakinumab (CAN) may provide significant long-term benefits. CAN…
Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
T. Bardin¹, A. So², R. Alten³, M. Bloch⁴, M. R. John⁵, G. Krammer⁵, J. M. Nebesky⁵, A. Tao⁶ and N. Schlesinger⁷, ¹Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ³Charité Univ Medicine, Berlin, Germany, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…